Skip to main content
Log in

Comparison of Health-Related Quality of Life Preferences Between Physicians and Cirrhotic Patients: Implications for Cost–Utility Analyses in Chronic Liver Disease

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Accurate assessment of utilities to calculate quality-adjusted life expectancy for medical interventions is needed in cirrhosis. To date, limited data exist in cirrhotics and are generally physician-assigned. Therefore, our aim was to determine utilities for six clinical scenarios in cirrhosis and to define if differences exist in utilities assigned by physicians versus patients. We administered a questionnaire to 83 physicians and 114 cirrhotics to obtain utilities using the time trade-off method for (1) compensated cirrhosis, (2) decompensated cirrhosis, (3) encephalopathy, (4) spontaneous bacterial peritonitis, (5) variceal bleeding, and (5) hepatocellular carcinoma. On a scale from 0 (death) to 1 (perfect health), mean utilities of physicians and patients were compared using the Student t test. One-way analysis of variance was used to compare the utilities between patients according to Child–Pugh class. Statistical significance was defined as a P value <0.05. The mean age of the physicians was 42±11, with 52% being male. The mean age of the patients was 52±9; with 59% male. The mean Child–Pugh score was 8±2 and HCV was the most common etiology (54%). The mean utilities for physicians and patients were as follows: CC, 0.78 vs. 0.88; DC, 0.55 vs. 0.74; E, 0.38 vs. 0.55; SBP, 0.33 vs. 0.45; VB, 0.27 vs. 0.40; and HCC, 0.19 vs. 0.30. All comparisons were statistically significant. Although physicians and patients assigned similar relative rankings to each health state, physicians assigned utilities were significantly different from those assigned by patients. These results suggest that studies that have used physician-assigned utilities do not accurately reflect patient preferences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization: World Health Organization Constitution. In Basic Documents. Geneva, World Health Organization, 1948

  2. Borgaonkar MR, Irvine EJ: Quality of life measurement in gastrointestinal and liver disorders. Gut 47:444-454, 2000

    Google Scholar 

  3. Brown RS Jr: Strategies and pitfalls in quality of life research. Hepatology 29:9S-12S, 1999

    Google Scholar 

  4. McGrew DM: Chronic illnesses and the end of life. Primary Care Clin Office Pract 28:339-347, 2001

    Google Scholar 

  5. Roth K, Lynn J, Zhong Z, et al.: Dying with end stage liver disease with cirrhosis: insights from SUPPORT. J Am Geriatr Soc 8:S122-S130, 2000

    Google Scholar 

  6. Schomerus H, Hamster W: Quality of life in cirrhotics with minimal hepatic encephalopathy. Met Brain Dis 16:37-41, 2001

    Google Scholar 

  7. Younossi ZM: Chronic liver disease and health-related quality of life. Am J Gastroenterol 120:305-307, 2001

    Google Scholar 

  8. Testa M, Simonson D: Assessment of quality of life outcomes. N Engl J Med 334:835-840, 1996

    Google Scholar 

  9. Wilson I, Cleary P: Linking clinical variables with health-related quality of life. JAMA 273:59-65, 1995

    Google Scholar 

  10. Bayliss MR: Methods in outcomes research in hepatology: Definitions and domains of quality of life. Hepatology 29:3S-6S, 1999

    Google Scholar 

  11. Younossi ZM, Guyatt G: Quality-of-life assessments and chronic liver disease. Am J Gastroenterol 93:1037-1041, 1998

    Google Scholar 

  12. Younossi ZM, et al.: Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 45:295-300, 1999

    Google Scholar 

  13. Gralnek IM, Hays RD, Kilbourne A, et al.: Development and evaluation of the Liver Disease Quality of Life Instrument in persons with advanced, chronic liver disease—The LDQOL 1.0. Am J Gastroenterol 95:3552-3565, 2000

    Google Scholar 

  14. Unal G, de Boer JB, Borsboom GJ, et al.: A psychometric comparison of health-related quality of life measures in chronic liver disease. J Clin Epidemiol 54:587-596, 2001

    Google Scholar 

  15. Yacavone RF, Locke GR, Provenzale DT, et al.: Quality of life measurement in gastroenterology: What is available? Am J Gastroenterol 96:285-297, 2001

    Google Scholar 

  16. Kaplan RM: Utility assessments for estimating quality-adjusted life-years. In Valuing Health Care, 1st ed. Sloan F (ed). New York, Cambridge University Press, 1995, pp 31-60

    Google Scholar 

  17. Younossi ZM, Boparai N, McCormick M, et al.: Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 96:579-583, 2001

    Google Scholar 

  18. Owens DK, Cardinalli AB, Nease RF Jr: Physicians' assessments of the utility of health states associated with the human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Qual Life Res 6:77-86, 1997

    Google Scholar 

  19. Younossi ZM, Boparai N, Price LL, et al.: Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 96:2199-2205, 2001

    Google Scholar 

  20. Hussain KB, Fontana RJ, Moyer CA, et al.: Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol 96:2737-2744, 2001

    Google Scholar 

  21. Forton DM, Taylor-Robinson SD, Thomas HC: Reduced quality of life in hepatitis C—Is it all in the head? J Hepatol 36:435-438, 2002

    Google Scholar 

  22. Fontana RJ, Moyer CA, Sonnad S, et al.: Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 96:170-178, 2001

    Google Scholar 

  23. Panel on Cost-effectiveness in Health and Medicine: Summary recommendations. In Cost-Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, and Weinstein MC (eds). New York, Oxford Univeristy Press, 1996, pp 304-311

    Google Scholar 

  24. Kim WR, Poterucha JJ, Hermans JE, et al.: Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med 127:866-874, 1997

    Google Scholar 

  25. Bennett WG, Inoue Y, Beck JR, et al.: Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 127:855-865, 1997

    Google Scholar 

  26. Tsevat J, Solzan JG, Kuntz S, et al.: Health values of patients infected with the human immunodeficiency virus. Med Care 34:44-57, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wells, C.D., Murrill, W.B. & Arguedas, M.R. Comparison of Health-Related Quality of Life Preferences Between Physicians and Cirrhotic Patients: Implications for Cost–Utility Analyses in Chronic Liver Disease. Dig Dis Sci 49, 453–458 (2004). https://doi.org/10.1023/B:DDAS.0000020502.46886.c1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:DDAS.0000020502.46886.c1

Navigation